Based on this signaling profile, we continued to investigate the effect of circRNA-SFMBT2 on the response to tamoxifen in patients with ER+ breast cancer from the TCGA and METABRIC databases via drug sensitivity prediction analysis using the oncoPredict R package [31]. This evidence concerns the gene SFMBT2 and breast carcinoma.